Ad
related to: fresenius pd product catalog- Contact Us
Send us a message to get in touch
and learn how we can help you.
- Parenteral Nutrition
Read more about how PN provides
nourishment to patients.
- The PN Portfolio
We develop innovations that nourish
so you can help patients flourish.
- Fresenius Kabi Resources
View our collection of webinars,
case studies, and more.
- Contact Us
Search results
Results from the WOW.Com Content Network
Fresenius Medical Care AG & Co. KGaA is a German healthcare company which provides kidney dialysis services through a network of 4,171 outpatient dialysis centers, serving 345,425 patients. [3] The company primarily treats end-stage renal disease (ESRD), which requires patients to undergo dialysis 3 times per week for the rest of their lives.
The second joint company of CSL Vifor with Fresenius is Vifor Fresenius Kabi focusing on marketing iron deficiency drugs in China. [27] CSL Vifor includes also Sanifit Therapeutics from Spain active in the field of calcification disorders in Chronic Kidney Disease. [28] Nephtera is a joint venture with Evotec to build a nephrology therapeutic ...
Fresenius SE & Co. KGaA is a European multinational health care company based in Bad Homburg vor der Höhe, Germany. It provides products and services for dialysis in hospitals, as well as inpatient and outpatient medical care. The company is involved in hospital management and in engineering and services for medical centers and other health ...
For premium support please call: 800-290-4726 more ways to reach us
Peritoneal dialysis (PD) is a type of dialysis that uses the peritoneum in a person's abdomen as the membrane through which fluid and dissolved substances are exchanged with the blood. [ 1 ] [ 2 ] It is used to remove excess fluid, correct electrolyte problems , and remove toxins in those with kidney failure . [ 3 ]
The user interface of pumps usually requests details on the type of infusion from the technician or nurse that sets them up: . Continuous infusion usually consists of small pulses of infusion, usually between 500 nanoliters and 10 milliliters, depending on the pump's design, with the rate of these pulses depending on the programmed infusion speed.
Fresenius Biotech conducted clinical trials and filed the drug for approval with the European Medicines Agency (EMA). It was approved in Europe on 20 April 2009. [9] In 2013, catumaxomab was voluntarily withdrawn from the US market and in 2017 in the EU market for commercial reasons. [10] The product had not been marketed in the EU since 2014. [11]
Sucroferric oxyhydroxide, sold under the brand name Velphoro, is a non-calcium, iron-based phosphate binder used for the control of serum phosphorus levels in adults with chronic kidney disease (CKD) on hemodialysis (HD) or peritoneal dialysis (PD). [6] It is used in form of chewable tablets. [5]
Ad
related to: fresenius pd product catalog